European Home Mechanical Ventilation Registry

Learn more about:
Related Clinical Trial
DMCRN-02-001: Assessing Pediatric Endpoints in DM1 Myotonic Dystrophy Type 1 and Resistance Exercise Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients Biomarker Development for Muscular Dystrophies Extracellular RNA Biomarkers of Myotonic Dystrophy Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1 Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1 Myotonic Dystrophy – Vascular and Cognition Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 Open Label Study in Adolescents and Children With Myotonic Disorders European Home Mechanical Ventilation Registry Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ? Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 Effects of a 12-week Strength Training Program in Men With Myotonic Dystrophy Type 1 Efficacy and Safety of DHEA for Myotonic Dystrophy Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1 Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 DM-IMT – Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1 Venous Thromboembolism in DM1 Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study) Children’s Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Observational Prolonged Trial in Myotonic Dystrophy Type 1 Venous Thromboembolism in Myotonic Dystrophy Type 1 Myotonic Dystrophy Type 1 Aerobic Exercise Study Multicenter Observational Study of Myotonic Dystrophy Type 1 DM1 Heart Registry – DM1 Respiratory Registry

Brief Title

European Home Mechanical Ventilation Registry

Official Title

European Home Mechanical Ventilation Registry

Brief Summary

      The European Home Mechanical Ventilation Registry (EHMVR) will enable a thorough evaluation
      of HMV by documenting the characteristics of HMV patients and their treatment. This will
      facilitate a prospective, observational study to identify the primary indications for HMV,
      describe patterns of HMV use in European countries, and characterize changes in the
      initiation and utilization of HMV over time. The registry will target all adult individuals
      who have an indication for HMV. In the EHMVR, patient data from routine clinical care will be
      documented using an electronic case report form (eCRF). The eCRF will record: patient
      demographic data; diagnostic information (including primary diagnosis, 6-minute walk time,
      the presence of depression, and quality of life); blood gases; ventilation treatment
      (including type of ventilator, modes and settings, interfaces used); follow-up data
      (including failure rates, side effects, technical issues). An initial Pilot Phase will be
      launched with the aim to enrol at least 200 patients over a 6-month period to determine the
      feasibility of the registry. Steering committee members and their institutions will be the
      main participants in the Pilot Phase. After completion of the Pilot Phase, the registry will
      be expanded across Europe with the goal of enrolling approximately 10,000 patients over 5

Detailed Description

      The data (baseline and follow-up) should be collected as part of routine clinical care. In
      clinical practice, after HMV initiation, the first control examination (follow-up number one)
      with nocturnal diagnostics should take place within the first 4-8 weeks. Annual follow-up is
      required, and it is recommended that subsequent control visits should be performed 1-2 times
      a year. Each patient will be included for 5 years (total duration of the registry).

Study Type

Observational [Patient Registry]

Primary Outcome

Determine the mortality rate and the number of hospital readmissions

Secondary Outcome

 Determine the effects of home mechanical ventilation on health-related quality of life using the EQ-5D and the Severe Respiratory Insufficiency questionnaires quality of life


Pulmonary Disease, Chronic Obstructive


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

August 2014

Completion Date

January 2019

Primary Completion Date

January 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Patients aged ≥18 years with an indication to receive HMV as part of routine clinical

          -  Patient is able to fully understand the study information and is willing to give
             informed consent

          -  Patient, or the patient's legal guardian, signing the consent form

        Exclusion Criteria:

        - No exclusion criteria have been defined because only data from routine clinical care are
        needed, plus a separate healthcare questionnaire




N/A - N/A

Accepts Healthy Volunteers



Jean-Louis Pepin, Pr, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor



 Clinical Trial Center North Hamburg Germany

Study Sponsor

Jean-Louis Pepin, Pr, Principal Investigator, Laboratoire d'EFCR, RDC Haut Chartreuse, CHU Michallon 38043,Grenoble, France

Verification Date

April 2020